Genital Warts - StatPearls - NCBI Bookshelf

The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Bookshelf Search databaseBooksAll DatabasesAssemblyBiocollectionsBioProjectBioSampleBooksClinVarConserved DomainsdbGaPdbVarGeneGenomeGEO DataSetsGEO ProfilesGTRIdentical Protein GroupsMedGenMeSHNLM CatalogNucleotideOMIMPMCProteinProtein ClustersProtein Family ModelsPubChem BioAssayPubChem CompoundPubChem SubstancePubMedSNPSRAStructureTaxonomyToolKitToolKitAllToolKitBookghSearch termSearch

• Browse Titles
• Advanced
• Help
• Disclaimer

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.

StatPearls [Internet].

Show detailsTreasure Island (FL): StatPearls Publishing; 2025 Jan-.Search term Condylomata Acuminata (Genital Warts)

Stephen W. Leslie; Hussain Sajjad; Sandeep Kumar.

Author Information and Affiliations

Authors

Stephen W. Leslie1; Hussain Sajjad2; Sandeep Kumar3.

Affiliations

1 Creighton University School of Medicine2 RMU and Allied Hospitals3 VA Medical Center

Last Update: December 13, 2025.

Continuing Education Activity

Genital warts (condyloma acuminata) represent the visible manifestation of infection with low-risk human papillomavirus types, most commonly HPV-6 and HPV-11, which account for about 90% of cases. This course reviews the wide range of presentations that clinicians may encounter, from small solitary lesions to extensive clusters involving the anogenital region. The diagnostic evaluation of condyloma acuminata, which relies primarily on visual inspection and is supported by biopsy when features suggest malignancy, when lesions are pigmented or ulcerated, or when the patient is immunocompromised, is also discussed. 

Additionally, this activity outlines the natural history of HPV, the limitations of diagnostic tools, such as the acetowhite effect, and the benefits and drawbacks of topical, ablative, and adjunctive therapies, as well as treatment selection and counseling. Participants will also gain a clearer understanding of HPV transmission dynamics, varied clinical presentations, and recurrence patterns. This activity for healthcare professionals is designed to enhance the learner's competence in identifying genital warts, selecting appropriate topical or surgical interventions, recognizing red-flag findings, coordinating sexually transmitted infection screening, guiding patients on expectations, precautions, and follow-up care, and implementing an appropriate interprofessional approach to manage this condition to improve patient outcomes.

Objectives:

• Identify the etiology of condyloma acuminata.
• Determine biopsy indications for the evaluation of condyloma acuminata.
• Evaluate the use of physically destructive therapies in the management of genital warts.
• Collaborate with interprofessional team members to improve collaboration of care and outcomes in patients with genital warts.

Access free multiple choice questions on this topic.

Introduction

Genital warts (condyloma acuminata) are the clinical manifestations of a sexually transmitted infection (STI) caused by some types of human papillomavirus (HPV).[1] Genital warts are a recognized symptom of genital HPV infections. About 90% of those exposed who contract HPV will not develop genital warts, and only about 10% who are infected will transmit the virus. Two types, HPV types 6 and 11, cause 90% of all genital warts.[2][3][4] The American Cancer Society reports that there are over 200 different known types of HPV, but only 14 are considered high-risk for possible malignant transformation, including anal, cervical, oropharyngeal, and penile cancers.[2][5][6][7][8][9][10][11]

Human papillomavirus is spread through direct skin-to-skin contact with an infected individual, usually during sex.[2][3] While some types of HPV cause cervical and anal cancer, these are not the same viral types that cause genital warts (see Image. Condylomata Acuminata).[12][13] Infection with different HPV types at the same time is also possible.[1]

Etiology

Human papillomavirus, including HPV types 6 and 11, which cause 90% of condyloma acuminata, is transmitted primarily through penetrative sex and less commonly through direct skin contact involving the anogenital area.[1][2][14] 

Epidemiology

Genital HPV infections have an estimated prevalence of 10% to 20%, with clinical manifestations (genital warts) in 1%.[2][15] The incidence of HPV infection has been increasing, with over 90% of sexually active men and 80% of sexually active women infected with HPV in their lifetime, and 80% of sexually active men and women becoming infected by age 45.[16][17] About 80% of those infected are between 17 and 33 years old, with the peak age group being 20 to 24.[16]

The overall prevalence of genital HPV infections in men aged 14 to 59 in the United States was 42.2%, with a prevalence of 45.2% for men aged 18 to 59.[18][19] The Centers for Disease Control (CDC) has estimated that 13 million new HPV infections are diagnosed annually in the United States, with over 42 million Americans already infected. The male-to-female ratio is about 1:1.[20] Older data indicated that genital warts are about twice as common in Caucasians as in African or Asian Americans, but more recent studies show that Black adults have the greatest incidence of high-risk genital HPV infections.[21][22][23][24]

Intraepidermal carcinoma (Bowen disease) of the penis, and about 35% to 40% of all penile cancers are associated with HPV infections.[25][26] Please see StatPearls' companion resource, "Intraepidermal Carcinoma," for further information. The median age for clearing of HPV infections in young men (16 to 24 years) is about 6 months, while in women, 90% will clear the infection in 2 years.[27][28]

Although treatments can remove warts, they do not remove HPV. Warts often regress spontaneously, but this is not guaranteed, and the process is slow as the body's immune system clears the virus. This often takes months or years, with about 65% of genital warts resolving on their own after 2 years without sequelae or scarring.[29][30][31] Traditional theories hold that the virus remains in the body for life. However, experts now believe that the virus may be cleared or suppressed to levels below the detection limit of polymerase chain reaction (PCR) tests.[32][33][34][35][36]

HPV infection appears to be the cause of most cases of anal cancer (about 90%) and virtually all cases of cervical cancer in women, with HPV type 16 accounting for about 50% of these (cervical cancer is the fourth most common cancer in women).[37] Some vulvar cancers have been linked to HPV infections (29% to 43%), while vaginal cancer is associated with HPV infections about 70% of the time (HPV Types 16 and 18).[38]

Risk factors for HPV infections and their persistence include the following:

• Age
• Age at first exposure to HPV
• Early sexual activity (particularly before 18 years)
• Failure to use sexual contact protection
• Genetic factors (polymorphisms in the human leukocyte antigen (HLA) system)
• Immunosuppressive state
• Increased cytokines like interleukin (IL-10, IL-6), and transforming growth factor (TGF-β1)
• Lack of HPV vaccination (especially among young men, whose vaccination rates are particularly low)
• Micronutrient deficiencies (beta-carotene, lutein, lycopene, tocopherols, vitamins C and E)
• Multiple sexual partners
• Simultaneous infection with multiple HPV types, HIV, or other STIs
• Smoking
• Use of oral contraceptives
• Viral factors and HPV type [39][40][41][42][43][44][45][46][47][48][49][50][51]

HPV Vaccinations

An HPV vaccination is available and recommended by the CDC for high-risk groups, particularly sexually active adolescents and young adults.[52][53] Recommendations include: 

• For previously unvaccinated adults, the CDC recommends vaccination for those aged 27 to 45. 
• For adolescents, the CDC recommends the vaccine be given at ages 11 or 12, but it may be started as early as 9.

Pathophysiology

The neoplastic mechanism of genital wart development involves the human papillomavirus (types 6 or 11) entering basal epithelial cells and using specific viral proteins to manipulate the host cell's growth cycle, leading to the formation of a benign tumor or wart. Fortunately, the HPV types (6 and 11) that cause 90% of anogenital warts have a low risk of malignant transformation.[2][3][4] The process is described in more detail as follows: 

• Viral entry occurs via microscopic skin cuts, ulcers, or abrasions, allowing viral access to metabolically active, rapidly replicating basal epithelial cells (keratinocytes).
• Initial contact with the basement membrane is facilitated by the major HPV capsid protein L1 binding to host heparan sulfate proteoglycans.[54]
• HPV entry into cells involves interactions between viral capsid proteins and proteases, as well as with various cellular receptors, ultimately leading to endocytosis and cellular internalization.[54]
• After cellular entry, the virus first localizes in the endosomal system, the endoplasmic reticulum, and the Golgi complex en route to the nucleus.[54]
• Once in the nucleus, the HPV genome becomes an extrachromosomal episome, protecting the virus from the immune response while enabling viral replication and spread via daughter cells.[54] 
• As infected cells migrate to the surface and begin to differentiate, cellular replication would normally stop.[54] However, the virus produces specific proteins, eg, E6 and E7, that allow cellular growth to continue.[54] 
• Tumor suppressor proteins p53 and pRb are strongly inactivated by high-risk HPV types, but not by the low-risk HPV types (HPV types 6 and 11) typically associated with genital warts.[2][3][4]
• These factors, taken together, keep infected cells in a constant, uninhibited proliferative state, leading to unchecked cellular growth and ultimately to the characteristic skin thickening, localized neoplastic enlargement, and protrusion of a genital wart.
• The body's natural immune system can often clear the virus, but if this fails, recurrences are likely even after successful treatment with apparent wart clearance.

Histopathology

Genital warts are typically diagnosed visually, with a confirmatory biopsy generally being unnecessary. The exophytic lesions result from enlargement of the dermal papillae and are lined by hyperplastic squamous epithelium that shows koilocytes, squamous epithelial cells characterized by an acentric, hyperchromatic nucleus displaced by a large perinuclear vacuole.[55] Patients with long-duration HPV infections, particularly with HPV types 16 and 18, are at risk for possible cancerous transformation of their HPV-associated lesions.[3][56][57][58][59][60]

History and Physical

Condylomata acuminata may occur separately or in clusters. They may be found in the anal or genital area, including the penile shaft, scrotum, vagina, or labia majora, as well as on the internal surfaces of the vagina and the anus (see Images. Female Genital Warts and Male Genital Warts).[3][61] Genital warts can be small (5 mm or less in diameter) or spread into large masses in the genital or anal areas, which is the common finding.[3] The color of these lesions varies from skin-colored to darker, and they may occasionally bleed spontaneously.[3] The appearance of genital warts depends on the site of infection, host factors, viral load, and the specific HPV type involved.[3][56]

In most cases, the only identifiable sign or symptom of an HPV infection is genital warts. Sometimes, condylomata acuminata may cause itching, redness, a burning sensation, increased moisture in the genital area, an unusual vaginal discharge, or discomfort, and they may also result in psychological distress.[3] Oropharyngeal involvement may cause additional symptoms, such as a persistent sore throat, chronic cough, hoarseness, pain on chewing, enlarged lymph glands, white or reddish tonsillar lesions, or an earache.

Clinical Signs of Malignancy

Signs of possible malignancy include the following:

• Bleeding
• Flat blueish-brown neoplasms 
• Irregular pigmentation
• Nonhealing ulcer
• Palpable evidence of dermal infiltration
• Penile rash
• Small, crusty bumps [3][26][62]

Evaluation

The diagnosis of condylomata acuminata is primarily made clinically, although a biopsy may be necessary for confirmation (see Image. Labial Condyloma Acuminata). Small warts may sometimes be confused with molluscum contagiosum. Genital warts typically rise above the skin surface, have parakeratosis, and demonstrate nuclear changes typical of HPV infections (nuclear enlargement with perinuclear clearing).[3] Because low-risk HPV types cause genital warts, DNA tests should not generally be used for diagnosis or in low-risk HPV infections. All patients with genital warts should be screened for STIs.[62]

The "acetowhite" effect is produced when a dilute 3% to 5% acetic acid (vinegar) solution is applied to the skin with a moistened gauze pad for 5 to 10 minutes, causing cells infected with HPV to turn white.[63][64][65] Acetic acid causes coagulation of intracellular proteins in cells with a high nuclear-to-cytoplasmic ratio, eg, those infected with HPV, those with psoriasis or candidiasis, and patients with precancerous or malignant lesions, which then appear opaque white.[63][64] 

While useful and sensitive in detecting even subclinical HPV skin infections, acetic acid is not very specific and can sometimes be misleading, with many false positives. Therefore, this test is not recommended for routine screening, and a biopsy may be needed for a definitive determination. The acetowhite effect can also be used as a cost-effective method of initial screening for cervical cancer in areas with limited medical resources, but this test is less sensitive and not as reliable as HPV DNA testing, which is preferred.[66][67][68] Biopsies are recommended if clinicians are uncertain about the diagnosis or if the patient is immunocompromised.[69] Pigmented and ulcerated lesions should also be considered for biopsy.[3]

Moreover, cystoscopy should be considered in patients with glans involvement, lower urinary tract symptoms, or significant urethral symptoms. In patients who have no symptoms, some experts have suggested waiting until any glans lesions have healed to avoid possible transfer of the HPV virus into the urethra.[70][71]

Treatment / Management

No known cure for HPV has been developed. Furthermore, removing visible warts does not necessarily reduce the transmission of the underlying HPV infection.[72][73][74] About 80% of individuals with HPV will clear the infection spontaneously within 18 to 24 months.[51][75][76] The American Urological Association does not recommend treating subclinical (invisible) lesions.

Factors that negatively affect the spontaneous clearance of HPV include a higher number of sexual partners, genetic factors, smoking, immunosuppression, coinfection with other STIs (eg, HIV, herpes simplex, Chlamydia trachomatis), multiparity, and longer use of oral contraceptives in women.[51][77][78][79][80][81]

Treatment of condyloma acuminata varies depending on the number, size, and location of warts. Additionally, treatment can cause permanent depigmentation, itching, pain, and scarring. Urethral meatus warts are best treated with surgery to minimize long-term complications. Treatments are either ablative (eg, vaporization, resection, coagulation, or excision) or topical agents.[3] Physically ablative treatments are more effective for wart removal, but in many cases, patients prefer topical agents as initial therapy, especially for smaller lesions.

Topical Therapies and Oral Agents 

Topical agents may be very effective, self-applied by patients, and less traumatic than surgical intervention. However, patient compliance is spotty, and recurrences are common.

Imiquimod

Imiquimod is a topical immune response cream applied to the affected area, but it may cause fungal infections and flu-like symptoms. Imiquimod is an immune enhancer that increases cytokine production (eg, tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), and interferon alpha).[82][83][84][85][86][87] This enhances a cytotoxic T-cell-mediated immune response.[85][88] Wart recurrence rates are lower than with podophyllin-based therapies, and imiquimod tends to result in healing without scarring.[89] 

The recommended application schedule for imiquimod 5% cream is 3 times per week.[90] The use of imiquimod 3.75% cream has been recommended as being equally effective while minimizing local adverse effects such as pain, burning, inflammation, itching, and erythema.[91][92][93] Usage may also be limited by cost, as the medication is relatively expensive if not covered by insurance. Imiquimod topical therapy is often effective when used adjunctively after ablative or surgical treatment.[86] It has a reported clearance rate of 35% to 68% with a recurrence rate of 6% to 26%.[3][62]

Isotretinoin

Isotretinoin is an oral medication typically used for acne, which is also available as a topical gel, though oral administration is more effective.[94] This medication reduces sebum production, shrinks sebaceous glands, exerts an anti-inflammatory effect, and has antibacterial benefits. Isotretinoin is generally reserved for recalcitrant, extensive, or intractable genital warts.[95] Isotretinoin has also shown significant efficacy when used as an adjunct to standard treatment for genital warts in immunocompromised patients, particularly when the condyloma is extensive or the lesions have proven resistant to initial therapy.[62][94][95][96][97][98]

Isotretinoin therapy is most effective when combined with other genital wart treatments, including surgical debulking, cryotherapy, interferon-alfa-2a, and topical imiquimod.[98][99][100] The standard or higher dosage protocol is 0.5 to 1 mg/kg/day, but a low-dose schedule of 0.3 mg/kg/day has also been used, albeit with a lower genital wart clearance rate. Standard topical therapy is continued during oral isotretinoin treatment.

Many potential adverse effects are associated with isotretinoin therapy, so it must be used cautiously. In particular, isotretinoin can cause very severe birth defects and should absolutely not be used in pregnancy.[101][102][103][104] For women of childbearing age, this means 2 pregnancy tests initially and monthly while on medication. They must also use 2 separate forms of birth control.

Adverse effects include dry skin, chapped lips, frequent nosebleeds, dry eyes, dry mouth, and severe sun sensitivity while on the medication. Additionally, night blindness, hair thinning, muscle aches, arthralgias, rashes, stomach problems, and higher cholesterol levels may occur. Liver damage, urethritis, and hydrocephalus have been reported but are quite rare.[105] Adverse effects are typically dose-dependent. A few reported cases of severe depression and suicide are associated with the use of isotretinoin, as well as possibly exacerbation of inflammatory bowel disease. For these reasons, isotretinoin is dosed at 30-day intervals and should be used cautiously.[96]

Higher-dose isotretinoin therapy has a genital wart clearance rate of about 56% to 76%, while the lower-dose treatment schedules have a lower reported clearance rate of approximately 35% to 45%.[106][107] Overall recurrence risk is about 12%, with lower rates (7.8%) observed with higher isotretinoin dosage schedules.[94][95][106][108] Recurrence rates with the lower-dose schedule are higher at 26%.[106]

Podophyllotoxin 

A 0.15% to 0.5% podophyllotoxin solution in a gel or cream can be applied to the affected area and is not washed off. Podofilox (an anti-mitotic drug) appears to be safer than podophyllin.[109] It works by binding microtubular subunits.[88] A recent meta-analysis concluded that podophyllotoxin-related therapies are overall the most effective.[86] The gel form is easier for patients to apply than the liquid with equal efficacy.[110] The recommended application schedule (apply BID for 3 days, then 4 days off, then repeat) can be confusing for some patients.

Adverse effects include localized burning, itching, pain, and inflammation. Podophyllotoxin-related therapies should not be used in pregnancy. The original precursor topical therapy, podophyllin, is no longer recommended by the CDC due to its high level of mutagens.[111] The reported clearance rate for podophyllotoxin-based topical therapy ranges from 45% to 83%, with a highly variable recurrence rate of up to 100%.[3][62]

Sinecatechins

Sinecatechins are an ointment of catechins extracted from green tea that appear to have a higher wart clearance rate than podophyllotoxin and imiquimod, while causing less local irritation, but clearance takes longer than with imiquimod. The overall genital wart clearance rate is reported to be 47% to 59%, with a recurrence rate of only 7% to 11%.[3][62][112]

Sinecatechins are available as a 15% ointment. The exact mechanism of action is unknown, but they have immunostimulatory, anti-proliferative, and anti-tumor properties and appear to work by reducing the expression of HPV gene products E6 and E7.[113] Adverse effects include local redness, inflammation, and pain.

Trichloroacetic acid

Trichloroacetic acid is not as effective as cryosurgery and should be avoided on the vagina, cervix, or urinary meatus.[55] This medication has a high recurrence rate and should be applied only by a healthcare practitioner due to the potential for injury to surrounding tissues.[114] Skin erosion and pain are most commonly reported with imiquimod and sinecatechins. The clearance rate for trichloroacetic acid topical therapy is 56% to 81% with a recurrence rate of 36%.[3][62]

Physical (Surgical) Removal or Destruction

Direct surgical excision or physically destructive therapies are considered more effective for keratinized warts, especially when they are more extensive[55]

Cryotherapy

Cryotherapy with liquid nitrogen is inexpensive, considered safe for use during pregnancy, and does not usually cause much scarring, but requires cryosurgical equipment and training. It may require anesthesia due to pain, and multiple treatments are often necessary. The reported genital wart clearance rate ranges from 44% to 75% with a recurrence rate of 21% to 42%.[3][62] 

Electrocauterization

Electrocauterization is considered adequate but causes scarring and requires some level of anesthesia.[55]

Laser vaporization

Laser vaporization with a CO2 laser has minimal bleeding but may be somewhat less effective than other ablative techniques. It is typically used for extensive areas of genital wart involvement, but it is relatively expensive and may cause a plume of virus-containing smoke.[115][116]

Photodynamic therapy

Photodynamic therapy with a photosensitizing agent (eg, aminolevulinic acid) has demonstrated efficacy in eliminating external genital warts.[117][118] The aminolevulinic acid is applied topically or directly intralesionally. The photosensitizing agent is quickly absorbed by the fastest-growing cells. Light exposure activates aminolevulinic acid, releasing free oxygen singlet radicals that directly destroy the wart by oxidative injury.[119][120][121][122] Photodynamic therapy has also been used successfully for genital warts in the pediatric age group and may be the single most effective treatment for urethral warts, albeit with a relatively high risk of complications.[121][123][124]

Photodynamic therapy for genital warts is currently considered off-label. However, this treatment is generally more effective, simpler, and has lower recurrence rates than CO2 laser therapy alone.[3][125] The reported genital wart clearance rate with phodynamic therapy ranges from about 63% to over 98%, with higher rates often requiring multiple sessions, while recurrence rates average about 17%.[126]

Surgical excision

Simple surgical excision under local anesthesia is simple and direct, but it will leave a scar and require a small surgical procedure.[72] Surgical removal under general anesthesia may be necessary for more extensive lesions, intra-anal warts, or in children.

Therapies No Longer Routinely Recommended

Therapies that are no longer recommended as standardized treatments include:

• Fluorouracil (5-FU) 5% cream is no longer considered an acceptable initial first-line therapy for genital warts due to adverse effects (pain, irritation, peeling of skin), questionable efficacy due to poor study quality, and the availability of multiple superior agents.[127]
• Interferon intralesional injections initially showed moderate efficacy, with a complete response rate of 36% to 63% as monotherapy, but other treatments have largely supplanted it.[91]
  • Interferon might still be considered for intractable cases as an adjunctive therapy.[91] 
• Podophyllin, podofilox, and especially isotretinoin should be avoided during pregnancy.[128][129]

Differential Diagnosis

Differential diagnoses that should be considered when evaluating patients for suspected condyloma acuminata include:

• Acrochordon [130]
• Benign familial pemphigus [131]
• Benign nevi [132]
• Buschke-Lowenstein tumor [133][134]
• Condyloma lata or secondary syphilis[135]
• Herpes simplex infection[136][137]
• Lichen planus[138]
• Malignancy (anal, cervical, oropharyngeal, penile, vulvar) [26][139][140][141][142][143]
• Molluscum contagiosum [144]
• Pearly penile papules [145]
• Penile cancer[26]
• Penile intraepithelial neoplasia [26]
• Psoriasis [146]
• Sebaceous cysts [147]
• Sexually transmitted diseases: 
  • Herpes simplex virus (HSV): Small, painful blisters that progress to ulcers and sores.[136][137]
  • Chancroid: Causes painful, soft-edged ulcers with soft edges.[148]
  • Granuloma inguinale (donovanosis): An infection that causes beefy-red, open sores.[149]
  • Lymphogranuloma venereum: A bacterial infection that starts as a small, painless sore.[150]Syphilis: This STI causes a single, painless ulcer (chancre).[151][152][135]
• Skin tags [153]
• Vulvar neurofibromatosis [154]

Prognosis

A large number of cases of condyloma acuminata fail to respond to treatment and often recur, especially with repeated infections from sexual contact or the long incubation period of HPV. Verifying patient compliance with therapy, changing the therapeutic agent, and adding isotretinoin can help. Morbidity associated with the disease is due to pruritus, bleeding, and the psychosocial burden of genital lesions, while mortality is due to its malignant transformation to squamous cell carcinoma. 

Immunocompromised patients are likely to have more resistant lesions and more frequent recurrences than the general population. They are also more likely to develop malignant transformation into squamous cell carcinoma.[155][156] In general, immunocompromised patients benefit from a combination of therapies, early addition of isotretinoin, longer treatment duration, and earlier surgical intervention.[157]

Complications

Local complications with disfigurement are the most common complications of condyloma acuminata. With untreated and advanced-stage disease, a risk of malignant transformation is present, which is the most feared complication. Buschke-Lowenstein tumors are a known complication of genital warts.[133][134] The current standard of care emphasizes treatment and primary prevention strategies, including vaccination, to prevent this devastating outcome. 

Deterrence and Patient Education

Gardasil is a vaccine that protects against human papillomavirus types 6, 11, 16, and 18. HPV types 16 and 18 cause an estimated 70% of all cervical cancers, and types 6 and 11 cause an estimated 90% of genital warts. The vaccine prevents the disease but is not therapeutic and must be given before exposure to the virus type to be effective.[53]

The vaccine was approved by the United States Food and Drug Administration (FDA) in 2006 for use in children as young as 9 years old, primarily for its prophylactic activity against cervical cancer.[53][158] Gardasil 9 was FDA-approved in 2014 to protect against the 4 HPV strains covered by the first-generation Gardasil, as well as 5 other HPV strains responsible for 20% of cervical cancers (HPV-31, HPV-33, HPV-45, HPV-52, and HPV-58).[53][158][159]

Vaccines are preventative and should not be considered therapeutic. Quadrivalent or 9-valent vaccines are recommended and generally preferred over bivalent vaccines. According to the Advisory Committee on Immunization Practices (ACIP), routine HPV vaccination is recommended for women aged 9 to 26, and it has demonstrated high efficacy through age 45.[53][158] The CDC advises that unvaccinated adults aged 26 to 45 may receive the vaccine after discussing it with their physician.[53][158]

The ACIP recommends routine HPV quadrivalent vaccination for males at age 11 to 12.[53][158] If not previously given or incomplete (the vaccine is a 3-dose series), the vaccine should be given through age 21.[53][158] From ages 22 to 26, the vaccine is considered optional.[53][158] In other words, the optimal age for male HPV vaccination is 11 to 12 years, but it may be administered up to age 45. 

More extensive and widespread use of human papillomavirus vaccines appears able to reduce the prevalence and penetration of HPV infections, complications, genital warts, and HPV-related malignancies.[52][160][161][162][163][164][165][166][167][168][169][170][171]

Pearls and Other Issues

Factors that should be kept in mind in the management of genital warts include:

• About 30% of genital warts will disappear within 4 months of their initial appearance.[2]
• According to the CDC and National Cancer Institute, human papillomavirus types 6 and 11 cause about 90% of genital warts, while HPV types 16 and 18 are associated with most cervical, vaginal, penile, and anal cancers.[2][3][4][26][58][59][139][140][141][172]
• Although 90% of HPV infections are cleared within 2 years of infection, it is possible for a latency period to occur, with the first occurrence or a recurrence happening months or even years later.[173][174]
• Anal or genital warts may be transmitted during birth and may be an indicator of sexual abuse.[175][176]
• Approximately 3 out of 4 unaffected partners of patients with genital warts develop warts within 8 months of contact with the affected individual.[2]
• Curcumin, a derivative of turmeric, has been reported anecdotally to be effective against genital warts, but further studies are needed to determine its safety and efficacy.[177][178]
• Experimentally, a nitric acid/zinc complex solution for topical application has been successfully used on difficult-to-treat warts. The solution includes dilute nitric acid, zinc, copper, and organic acids.[179][180]
  • The application of this solution causes destruction and desiccation of the wart through a combination of denaturation and active protein coagulation actions.[179][180]
  • So far, it appears to be well-tolerated and effective.[179][180]
• Genital warts may sometimes result from autoinoculation by warts elsewhere on the body, eg, from the hands.[181]
• HPV can remain latent for months or years before progressing to the growth of genital warts.[51]
• In individuals with a prior HPV infection, the appearance of new warts may be either from a new exposure or a recurrence.[182]
• Latent HPV without visible warts is transmissible, and if an individual has unprotected sex with an infected partner, there is a 70% chance they will become infected.[183]
• Most genital warts will recur within 3 months of completion of initial therapy, even if therapy was followed correctly.[2] 
• Recurrence rates depend on the patient's general health and immune status, previous HPV vaccinations, specific HPV strain, number of inoculations (sexual frequency with an infected partner), use of condoms, and the viral load.[182][184]
• Smoking increases the risk of getting genital warts from HPV.[185][186][187]
• Condom use is recommended and is generally considered helpful, but it only offers incomplete protection from transmission of HPV and genital warts.[188][189][190][191][192]
• Topical antivirals, such as cidofovir, appear promising, but further study is needed before they can be safely used clinically.[193][194][195][196]
• Virus transmission and infection are less likely but may still occur even without any visible genital warts.[3][197]

Enhancing Healthcare Team Outcomes

Genital warts represent a common clinical manifestation of infection with low-risk HPV types, most frequently HPV-6 and HPV-11. Condyloma acuminata lesions may appear singly or in clusters and can involve the genital, anal, or oropharyngeal regions, with presentations influenced by host factors, viral load, and HPV type. Diagnosis relies on visual assessment, with biopsy reserved for atypical, pigmented, ulcerated, or uncertain lesions. Management includes topical, ablative, and adjunctive therapies, yet recurrence remains common. Prevention plays a central role, as quadrivalent HPV vaccination significantly reduces HPV-related infections, genital warts, and associated malignancies.

Effective care requires coordinated, interprofessional collaboration among physicians, general practitioners, advanced practitioners, nurses, pharmacists, and allied health professionals. Clinicians must use strong communication skills to educate patients and families on HPV transmission, the natural history of infection, and evidence-based treatment options. A unified strategy ensures timely diagnosis, appropriate therapy selection, and consistent counseling regarding HPV vaccination, which is recommended routinely at age 11 or 12 and permitted starting at age 9, with catch-up vaccination through age 26. Shared decision-making between clinicians and adults aged 27 through 45 supports individualized vaccination choices. Interprofessional coordination strengthens patient-centered care, enhances safety, and improves long-term outcomes.[53]

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

Figure

Female Genital Warts. Condylomata acuminata in females may be found in the anal or genital area, including the vagina or labia majora, as well as on the internal surfaces of the vagina and the anus. DermNet New Zealand

Figure

Male Genital Warts. Condylomata acuminata in males may be found in the anal or genital area, including the penile shaft, scrotum, and on the internal surfaces of the anus. DermNet New Zealand

Figure

Condylomata Acuminata. Genital warts (condyloma acuminata) are the clinical manifestations of a sexually transmitted infection (STI) caused by some types of human papillomavirus (HPV). Contributed by S Bhimji, MD

Figure

Labial Condyloma Acuminata.  The diagnosis of condylomata acuminata is primarily made clinically, although a biopsy may be necessary for confirmation. Contributed by S Verma, MBBS, DVD, FRCP, FAAD

References

1.Sendagorta-Cudós E, Burgos-Cibrián J, Rodríguez-Iglesias M. Genital infections due to the human papillomavirus. Enferm Infecc Microbiol Clin (Engl Ed). 2019 May;37(5):324-334. [PubMed: 30853139]2.Yanofsky VR, Patel RV, Goldenberg G. Genital warts: a comprehensive review. J Clin Aesthet Dermatol. 2012 Jun;5(6):25-36. [PMC free article: PMC3390234] [PubMed: 22768354]3.Pennycook KB, McCready TA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jun 21, 2023. Condyloma Acuminata. [PubMed: 31613447]4.Brianti P, De Flammineis E, Mercuri SR. Review of HPV-related diseases and cancers. New Microbiol. 2017 Apr;40(2):80-85. [PubMed: 28368072]5.Iorga L, Dragos Marcu R, Cristina Diaconu C, Maria Alexandra Stanescu A, Pantea Stoian A, Liviu Dorel Mischianu D, Surcel M, Bungau S, Constantin T, Boda D, Fekete L, Gabriel Bratu O. Penile carcinoma and HPV infection (Review). Exp Ther Med. 2020 Jul;20(1):91-96. [PMC free article: PMC7273896] [PubMed: 32518604]6.Soheili M, Keyvani H, Soheili M, Nasseri S. Human papilloma virus: A review study of epidemiology, carcinogenesis, diagnostic methods, and treatment of all HPV-related cancers. Med J Islam Repub Iran. 2021;35:65. [PMC free article: PMC8278030] [PubMed: 34277502]7.Roman BR, Aragones A. Epidemiology and incidence of HPV-related cancers of the head and neck. J Surg Oncol. 2021 Nov;124(6):920-922. [PMC free article: PMC8552291] [PubMed: 34558067]8.Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(Suppl 1):28-44. [PMC free article: PMC9298213] [PubMed: 34669203]9.Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002 Apr;55(4):244-65. [PMC free article: PMC1769629] [PubMed: 11919208]10.Sabatini ME, Chiocca S. Human papillomavirus as a driver of head and neck cancers. Br J Cancer. 2020 Feb;122(3):306-314. [PMC free article: PMC7000688] [PubMed: 31708575]11.Spence T, Bruce J, Yip KW, Liu FF. HPV Associated Head and Neck Cancer. Cancers (Basel). 2016 Aug 05;8(8) [PMC free article: PMC4999784] [PubMed: 27527216]12.Malagón T, Louvanto K, Wissing M, Burchell AN, Tellier PP, El-Zein M, Coutlée F, Franco EL. Hand-to-genital and genital-to-genital transmission of human papillomaviruses between male and female sexual partners (HITCH): a prospective cohort study. Lancet Infect Dis. 2019 Mar;19(3):317-326. [PMC free article: PMC6404546] [PubMed: 30745276]13.Dillner J. Some clear answers regarding transmission of genital human papillomavirus. Lancet Infect Dis. 2019 Mar;19(3):227-228. [PubMed: 30745275]14.Ozaydin-Yavuz G, Bilgili SG, Guducuoglu H, Yavuz IH, Elibuyuk-Aksac S, Karadag AS. Determinants of high-risk human papillomavirus infection in anogenital warts. Postepy Dermatol Alergol. 2019 Feb;36(1):76-81. [PMC free article: PMC6409869] [PubMed: 30858783]15.Juckett G, Hartman-Adams H. Human papillomavirus: clinical manifestations and prevention. Am Fam Physician. 2010 Nov 15;82(10):1209-13. [PubMed: 21121531]16.Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014 Nov;41(11):660-4. [PMC free article: PMC6745688] [PubMed: 25299412]17.Tao Y, Shao H, Zhang T, Pu J, Tang C. Factors Influencing Men's Attitudes toward HPV Vaccination in Males Included in the Chinese National Immunization Program. Vaccines (Basel). 2022 Jun 30;10(7) [PMC free article: PMC9319647] [PubMed: 35891217]18.Han JJ, Beltran TH, Song JW, Klaric J, Choi YS. Prevalence of Genital Human Papillomavirus Infection and Human Papillomavirus Vaccination Rates Among US Adult Men: National Health and Nutrition Examination Survey (NHANES) 2013-2014. JAMA Oncol. 2017 Jun 01;3(6):810-816. [PMC free article: PMC5540044] [PubMed: 28114440]19.Gargano JW, Unger ER, Liu G, Steinau M, Meites E, Dunne E, Markowitz LE. Prevalence of Genital Human Papillomavirus in Males, United States, 2013-2014. J Infect Dis. 2017 Apr 01;215(7):1070-1079. [PubMed: 28170037]20.Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis. 2013 Jan 25;13:39. [PMC free article: PMC3618302] [PubMed: 23347441]21.Short SL, Stockman DL, Wolinsky SM, Trupei MA, Moore J, Reichman RC. Comparative rates of sexually transmitted diseases among heterosexual men, homosexual men, and heterosexual women. Sex Transm Dis. 1984 Oct-Dec;11(4):271-4. [PubMed: 6549226]22.Lin L, Benard VB, Greek A, Hawkins NA, Roland KB, Saraiya M. Racial and ethnic differences in human papillomavirus positivity and risk factors among low-income women in Federally Qualified Health Centers in the United States. Prev Med. 2015 Dec;81:258-61. [PMC free article: PMC4751981] [PubMed: 26361751]23.Cofie LE, Xu L, Alligood B, Bhagat N, Maness S, Lee MH, Richman A. Nativity and racial/ethnic differences in HPV infection among U.S. adults, NHANES 2007-2016. Front Public Health. 2025;13:1604954. [PMC free article: PMC12457335] [PubMed: 41000317]24.Banister CE, Messersmith AR, Cai B, Spiryda LB, Glover SH, Pirisi L, Creek KE. Disparity in the persistence of high-risk human papillomavirus genotypes between African American and European American women of college age. J Infect Dis. 2015 Jan 01;211(1):100-8. [PMC free article: PMC4326315] [PubMed: 25028692]25.Stratton KL, Culkin DJ. A Contemporary Review of HPV and Penile Cancer. Oncology (Williston Park). 2016 Mar;30(3):245-9. [PubMed: 26984219]26.Engelsgjerd JS, Leslie SW, LaGrange CA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Sep 2, 2024. Penile Cancer and Penile Intraepithelial Neoplasia. [PubMed: 29763105]27.Moreira ED, Giuliano AR, Palefsky J, Flores CA, Goldstone S, Ferris D, Hillman RJ, Moi H, Stoler MH, Marshall B, Vuocolo S, Guris D, Haupt RM. Incidence, clearance, and disease progression of genital human papillomavirus infection in heterosexual men. J Infect Dis. 2014 Jul 15;210(2):192-9. [PubMed: 24495910]28.Rodríguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, Solomon D, Burk R., Proyecto Epidemiológico Guanacaste Group. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008 Apr 02;100(7):513-7. [PMC free article: PMC3705579] [PubMed: 18364507]29.Bender ME. Concepts of wart regression. Arch Dermatol. 1986 Jun;122(6):644-7. [PubMed: 3013101]30.Jin SP, Jeon YK, Cho KH, Chung JH. A rapidly regressing wart following biopsy. Ann Dermatol. 2011 Feb;23(1):123-4. [PMC free article: PMC3119993] [PubMed: 21738382]31.Coleman N, Birley HD, Renton AM, Hanna NF, Ryait BK, Byrne M, Taylor-Robinson D, Stanley MA. Immunological events in regressing genital warts. Am J Clin Pathol. 1994 Dec;102(6):768-74. [PubMed: 7801889]32.Jin J, Li S, Huang H, Li J, Lyu Y, Ran Y, Chang H, Zhao X. Development of human papillomavirus and its detection methods (Review). Exp Ther Med. 2024 Oct;28(4):382. [PMC free article: PMC11332130] [PubMed: 39161614]33.Ren W, Jin Y, Shi L, Chen H, Zhang Z, Wang Y, Zhai T, Huang J. The necessity and challenges of human papillomavirus testing for men. Front Cell Infect Microbiol. 2025;15:1563499. [PMC free article: PMC12256477] [PubMed: 40661973]34.Tao X, Zheng B, Yin F, Zeng Z, Li Z, Griffith CC, Luo B, Ding X, Zhou X, Zhao C. Polymerase Chain Reaction Human Papillomavirus (HPV) Detection and HPV Genotyping in Invasive Cervical Cancers With Prior Negative HC2 Test Results. Am J Clin Pathol. 2017 May 01;147(5):477-483. [PubMed: 28340235]35.Cubie HA, Seagar AL, McGoogan E, Whitehead J, Brass A, Arends MJ, Whitley MW. Rapid real time PCR to distinguish between high risk human papillomavirus types 16 and 18. Mol Pathol. 2001 Feb;54(1):24-9. [PMC free article: PMC1186996] [PubMed: 11212885]36.Park B-M, Kim S, Choi J, Song Y, Park S. Accuracy of real-time PCR assays for human papillomavirus using urine samples: a systematic review and meta-analysis. J Clin Microbiol. 2025 May 14;63(5):e0135224. [PMC free article: PMC12077123] [PubMed: 40162806]37.Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003 Jan;16(1):1-17. [PMC free article: PMC145302] [PubMed: 12525422]38.Lisboa C, Santo I, Azevedo J, Azevedo L, Pista A, Dias C, Cunha MJ. High Prevalence of Human Papillomavirus on Anal and Oral Samples from Men and Women with External Anogenital Warts: The HERCOLES Study. Acta Derm Venereol. 2019 May 01;99(6):557-563. [PubMed: 30723872]39.Sichero L, Giuliano AR, Villa LL. Human Papillomavirus and Genital Disease in Men: What We Have Learned from the HIM Study. Acta Cytol. 2019;63(2):109-117. [PubMed: 30799416]40.Dempsey AF. Human papillomavirus: the usefulness of risk factors in determining who should get vaccinated. Rev Obstet Gynecol. 2008 Summer;1(3):122-8. [PMC free article: PMC2582644] [PubMed: 19015763]41.Silins I, Ryd W, Strand A, Wadell G, Törnberg S, Hansson BG, Wang X, Arnheim L, Dahl V, Bremell D, Persson K, Dillner J, Rylander E. Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer. 2005 Aug 10;116(1):110-5. [PubMed: 15756673]42.Castle PE, Giuliano AR. Chapter 4: Genital tract infections, cervical inflammation, and antioxidant nutrients--assessing their roles as human papillomavirus cofactors. J Natl Cancer Inst Monogr. 2003;(31):29-34. [PubMed: 12807942]43.Zhang P. Composite dietary antioxidant index and HPV infection from single and mixed associations to SHAP-interpreted machine learning predictions. Front Nutr. 2025;12:1619742. [PMC free article: PMC12350107] [PubMed: 40823022]44.Siegel EM, Craft NE, Duarte-Franco E, Villa LL, Franco EL, Giuliano AR. Associations between serum carotenoids and tocopherols and type-specific HPV persistence: the Ludwig-McGill cohort study. Int J Cancer. 2007 Feb 01;120(3):672-80. [PMC free article: PMC3458424] [PubMed: 17096322]45.Strickler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, Massad LS, Hall C, Bacon M, Levine AM, Watts DH, Silverberg MJ, Xue X, Schlecht NF, Melnick S, Palefsky JM. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst. 2005 Apr 20;97(8):577-86. [PubMed: 15840880]46.Giuliano AR, Siegel EM, Roe DJ, Ferreira S, Baggio ML, Galan L, Duarte-Franco E, Villa LL, Rohan TE, Marshall JR, Franco EL., Ludwig-McGill HPV Natural History Study. Dietary intake and risk of persistent human papillomavirus (HPV) infection: the Ludwig-McGill HPV Natural History Study. J Infect Dis. 2003 Nov 15;188(10):1508-16. [PubMed: 14624376]47.Sammarco ML, Del Riccio I, Tamburro M, Grasso GM, Ripabelli G. Type-specific persistence and associated risk factors of human papillomavirus infections in women living in central Italy. Eur J Obstet Gynecol Reprod Biol. 2013 Jun;168(2):222-6. [PubMed: 23395560]48.Richardson H, Abrahamowicz M, Tellier PP, Kelsall G, du Berger R, Ferenczy A, Coutlée F, Franco EL. Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1149-56. [PubMed: 15894665]49.Maciag PC, Schlecht NF, Souza PS, Rohan TE, Franco EL, Villa LL. Polymorphisms of the human leukocyte antigen DRB1 and DQB1 genes and the natural history of human papillomavirus infection. J Infect Dis. 2002 Jul 15;186(2):164-72. [PubMed: 12134251]50.Wang SS, Hildesheim A. Chapter 5: Viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr. 2003;(31):35-40. [PubMed: 12807943]51.Huber J, Mueller A, Sailer M, Regidor PA. Human papillomavirus persistence or clearance after infection in reproductive age. What is the status? Review of the literature and new data of a vaginal gel containing silicate dioxide, citric acid, and selenite. Womens Health (Lond). 2021 Jan-Dec;17:17455065211020702. [PMC free article: PMC8785287] [PubMed: 34096424]52.Hristamyan MA. Primary and Secondary Prophylaxis for Diseases Caused by Human Papillomavirus Infections. J Cancer Prev. 2025 Sep 30;30(3):146-153. [PMC free article: PMC12527971] [PubMed: 41112418]53.Soca Gallego L, Dominguez A, Parmar M. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Feb 19, 2024. Human Papilloma Virus Vaccine. [PubMed: 32965857]54.Aksoy P, Gottschalk EY, Meneses PI. HPV entry into cells. Mutat Res Rev Mutat Res. 2017 Apr-Jun;772:13-22. [PMC free article: PMC5443120] [PubMed: 28528686]55.Leung AK, Barankin B, Leong KF, Hon KL. Penile warts: an update on their evaluation and management. Drugs Context. 2018;7:212563. [PMC free article: PMC6302884] [PubMed: 30622585]56.Costa-Silva M, Fernandes I, Rodrigues AG, Lisboa C. Anogenital warts in pediatric population. An Bras Dermatol. 2017 Sep-Oct;92(5):675-681. [PMC free article: PMC5674701] [PubMed: 29166505]57.Bodily J, Laimins LA. Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol. 2011 Jan;19(1):33-9. [PMC free article: PMC3059725] [PubMed: 21050765]58.Baba SK, Alblooshi SSE, Yaqoob R, Behl S, Al Saleem M, Rakha EA, Malik F, Singh M, Macha MA, Akhtar MK, Houry WA, Bhat AA, Al Menhali A, Zheng ZM, Mirza S. Human papilloma virus (HPV) mediated cancers: an insightful update. J Transl Med. 2025 Apr 29;23(1):483. [PMC free article: PMC12039116] [PubMed: 40301924]59.Balhara N, Yadav R, Ranga S, Ahuja P, Tanwar M. Understanding the HPV associated cancers: A comprehensive review. Mol Biol Rep. 2024 Jun 14;51(1):743. [PubMed: 38874682]60.Janiszewska J, Kostrzewska-Poczekaj M, Wierzbicka M, Brenner JC, Giefing M. HPV-driven oncogenesis-much more than the E6 and E7 oncoproteins. J Appl Genet. 2025 Feb;66(1):63-71. [PMC free article: PMC11761861] [PubMed: 38907809]61.Sykes NL. Condyloma acuminatum. Int J Dermatol. 1995 May;34(5):297-302. [PubMed: 7541783]62.Lacey CJ, Woodhall SC, Wikstrom A, Ross J. 2012 European guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol. 2013 Mar;27(3):e263-70. [PubMed: 22409368]63.Kumar B, Gupta S. The acetowhite test in genital human papillomavirus infection in men: what does it add? J Eur Acad Dermatol Venereol. 2001 Jan;15(1):27-9. [PubMed: 11451317]64.Wikström A, Hedblad MA, Johansson B, Kalantari M, Syrjänen S, Lindberg M, von Krogh G. The acetic acid test in evaluation of subclinical genital papillomavirus infection: a comparative study on penoscopy, histopathology, virology and scanning electron microscopy findings. Genitourin Med. 1992 Apr;68(2):90-9. [PMC free article: PMC1194819] [PubMed: 1316310]65.Dixit R, Bhavsar C, Marfatia YS. Laboratory diagnosis of human papillomavirus virus infection in female genital tract. Indian J Sex Transm Dis AIDS. 2011 Jan;32(1):50-2. [PMC free article: PMC3139291] [PubMed: 21799579]66.Mustafa MS, Jindal AK, Singh P. Visual Inspection using Acetic Acid for Cervical Cancer in Low Resource Settings. Med J Armed Forces India. 2010 Oct;66(4):382-4. [PMC free article: PMC4919830] [PubMed: 27365747]67.Bogale AL, Teklehaymanot T, Kassie GM, Medhin G, Ali JH, Belay NB. Performance of visual Inspection With Acetic Acid for Cervical Cancer Screening as Compared to Human papillomavirus Deoxyribonucleic acid Testing Among Women With HIV in Ethiopia: A Comparative Cross-sectional Study. Cancer Control. 2022 Jan-Dec;29:10732748221114980. [PMC free article: PMC9284200] [PubMed: 35829643]68.Sauvaget C, Fayette JM, Muwonge R, Wesley R, Sankaranarayanan R. Accuracy of visual inspection with acetic acid for cervical cancer screening. Int J Gynaecol Obstet. 2011 Apr;113(1):14-24. [PubMed: 21257169]69.Maw R., HPV Special Interest Group of BASHH. Anogenital warts. Sex Transm Infect. 2006 Dec;82 Suppl 4(Suppl 4):iv40-1. [PMC free article: PMC2563897] [PubMed: 17151053]70.Zayko MO, Velilla RE, Shurbaji MS. Condyloma Acuminata Presenting as Isolated Papillary Lesions in the Prostatic Urethra. Am J Case Rep. 2018 Dec 22;19:1522-1525. [PMC free article: PMC6320550] [PubMed: 30578409]71.Iskander M, Patrick N, Mistry R. Intra urethral human papillomavirus related warts following urinary tract instrumentation. Urol J. 2014 May 06;11(2):1491. [PubMed: 24807766]72.Beutner KR, Reitano MV, Richwald GA, Wiley DJ. External genital warts: report of the American Medical Association Consensus Conference. AMA Expert Panel on External Genital Warts. Clin Infect Dis. 1998 Oct;27(4):796-806. [PubMed: 9798036]73.Wiley DJ, Douglas J, Beutner K, Cox T, Fife K, Moscicki AB, Fukumoto L. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis. 2002 Oct 15;35(Suppl 2):S210-24. [PubMed: 12353208]74.Workowski KA, Bolan GA., Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015 Jun 05;64(RR-03):1-137. [PMC free article: PMC5885289] [PubMed: 26042815]75.Gravitt PE. The known unknowns of HPV natural history. J Clin Invest. 2011 Dec;121(12):4593-9. [PMC free article: PMC3225991] [PubMed: 22133884]76.Shanmugasundaram S, You J. Targeting Persistent Human Papillomavirus Infection. Viruses. 2017 Aug 18;9(8) [PMC free article: PMC5580486] [PubMed: 28820433]77.Jensen KE, Schmiedel S, Norrild B, Frederiksen K, Iftner T, Kjaer SK. Parity as a cofactor for high-grade cervical disease among women with persistent human papillomavirus infection: a 13-year follow-up. Br J Cancer. 2013 Jan 15;108(1):234-9. [PMC free article: PMC3553518] [PubMed: 23169283]78.Castellsagué X, Muñoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. 2003;(31):20-8. [PubMed: 12807941]79.Yetimalar H, Kasap B, Cukurova K, Yildiz A, Keklik A, Soylu F. Cofactors in human papillomavirus infection and cervical carcinogenesis. Arch Gynecol Obstet. 2012 Mar;285(3):805-10. [PubMed: 21830008]80.Arnheim Dahlström L, Andersson K, Luostarinen T, Thoresen S, Ögmundsdottír H, Tryggvadottír L, Wiklund F, Skare GB, Eklund C, Sjölin K, Jellum E, Koskela P, Wadell G, Lehtinen M, Dillner J. Prospective seroepidemiologic study of human papillomavirus and other risk factors in cervical cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2541-50. [PubMed: 21994401]81.International Collaboration of Epidemiological Studies of Cervical Cancer. Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, Goodhill A, Green J, Peto J, Plummer M, Sweetland S. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007 Nov 10;370(9599):1609-21. [PubMed: 17993361]82.Shi W, Yao X, Fu Y, Wang Y. Interferon-α and its effects on cancer cell apoptosis. Oncol Lett. 2022 Jul;24(1):235. [PMC free article: PMC9185151] [PubMed: 35720476]83.Cha L, Berry CM, Nolan D, Castley A, Fernandez S, French MA. Interferon-alpha, immune activation and immune dysfunction in treated HIV infection. Clin Transl Immunology. 2014 Feb;3(2):e10. [PMC free article: PMC4232062] [PubMed: 25505958]84.Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, Lee SR, Yang SH. The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics. Int J Mol Sci. 2021 Mar 08;22(5) [PMC free article: PMC7962638] [PubMed: 33800290]85.Beutner KR, Tyring SK, Trofatter KF, Douglas JM, Spruance S, Owens ML, Fox TL, Hougham AJ, Schmitt KA. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother. 1998 Apr;42(4):789-94. [PMC free article: PMC105543] [PubMed: 9559784]86.Bertolotti A, Ferdynus C, Milpied B, Dupin N, Huiart L, Derancourt C. Local Management of Anogenital Warts in Non-Immunocompromised Adults: A Network Meta-Analysis of Randomized Controlled Trials. Dermatol Ther (Heidelb). 2020 Apr;10(2):249-262. [PMC free article: PMC7090115] [PubMed: 32030564]87.Urosevic M, Maier T, Benninghoff B, Slade H, Burg G, Dummer R. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol. 2003 Oct;139(10):1325-32. [PubMed: 14568837]88.Brown TJ, Yen-Moore A, Tyring SK. An overview of sexually transmitted diseases. Part II. J Am Acad Dermatol. 1999 Nov;41(5 Pt 1):661-77; quiz 678-80. [PubMed: 10534627]89.Severson J, Evans TY, Lee P, Chan T, Arany I, Tyring SK. Human papillomavirus infections: epidemiology, pathogenesis, and therapy. J Cutan Med Surg. 2001 Jan-Feb;5(1):43-60. [PubMed: 11281434]90.Gotovtseva EP, Kapadia AS, Smolensky MH, Lairson DR. Optimal frequency of imiquimod (aldara) 5% cream for the treatment of external genital warts in immunocompetent adults: a meta-analysis. Sex Transm Dis. 2008 Apr;35(4):346-51. [PubMed: 18360317]91.Czelusta AJ, Evans T, Arany I, Tyring SK. A guide to immunotherapy of genital warts: focus on interferon and imiquimod. BioDrugs. 1999 May;11(5):319-32. [PubMed: 18031142]92.Berman B, Wolf J. The role of imiquimod 3.75% cream in the treatment of external genital warts. Skin Therapy Lett. 2012 Apr;17(4):5-7. [PubMed: 22491804]93.Rosen T, Nelson A, Ault K. Imiquimod cream 2.5% and 3.75% applied once daily to treat external genital warts in men. Cutis. 2015 Oct;96(4):277-82. [PubMed: 26682290]94.Oren-Shabtai M, Snast I, Lapidoth M, Sherman S, Noyman Y, Mimouni D, Hodak E, Levi A. Topical and Systemic Retinoids for the Treatment of Genital Warts: A Systematic Review and Meta-Analysis. Dermatology. 2021;237(3):389-395. [PubMed: 33279886]95.Sivasankari M, Adityan MS. Oral isotretinoin as first-line systemic therapy in a case of extensive genital warts. Indian J Sex Transm Dis AIDS. 2022 Jan-Jun;43(1):70-72. [PMC free article: PMC9282684] [PubMed: 35846534]96.Jha AK, Sonthalia S, Ganguly S. Oral isotretinoin as an adjunctive treatment for recurrent genital warts. J Am Acad Dermatol. 2018 Feb;78(2):e35-e36. [PubMed: 29332721]97.Nickle SB, Peterson N, Peterson M. Updated Physician's Guide to the Off-label Uses of Oral Isotretinoin. J Clin Aesthet Dermatol. 2014 Apr;7(4):22-34. [PMC free article: PMC3990537] [PubMed: 24765227]98.Yew YW, Pan JY. Complete remission of recalcitrant genital warts with a combination approach of surgical debulking and oral isotretinoin in a patient with systemic lupus erythematosus. Dermatol Ther. 2014 Mar-Apr;27(2):79-82. [PubMed: 24703263]99.Cardamakis E, Kotoulas IG, Relakis K, Metalinos K, Michopoulos J, Stathopoulos E, Mantouvalos H. Comparative study of systemic interferon alfa-2a plus isotretinoin versus isotretinoin in the treatment of recurrent condyloma acuminatum in men. Urology. 1995 May;45(5):857-60. [PubMed: 7747375]100.Erkek E, Basar H, Bozdogan O, Emeksiz MC. Giant condyloma acuminata of Buschke-Löwenstein: successful treatment with a combination of surgical excision, oral acitretin and topical imiquimod. Clin Exp Dermatol. 2009 Apr;34(3):366-8. [PubMed: 19175780]101.Sladden MJ, Harman KE. What is the chance of a normal pregnancy in a woman whose fetus has been exposed to isotretinoin? Arch Dermatol. 2007 Sep;143(9):1187-8. [PubMed: 17875883]102.Revuz J. [Isotretinoin and pregnancy]. Ann Dermatol Venereol. 2000 Oct;127(10):797-8. [PubMed: 11060380]103.Centers for Disease Control (CDC). Isotretinoin--a newly recognized human teratogen. MMWR Morb Mortal Wkly Rep. 1984 Apr 06;33(13):171-3. [PubMed: 6422237]104.Perlman SE, Leach EE, Dominguez L, Ruszkowski AM, Rudy SJ. "Be smart, be safe, be sure". The revised Pregnancy Prevention Program for women on isotretinoin. J Reprod Med. 2001 Feb;46(2 Suppl):179-85. [PubMed: 11255826]105.Paredes-Bhushan V, Rezaee ME, Chavez DR. Isotretinoin induced urethritis: A case report & review of the literature. Urol Case Rep. 2020 Mar;29:101109. [PMC free article: PMC6939063] [PubMed: 31908966]106.Nofal A, Fawzy MM, Eldeeb F, Nofal H, El-Hawary EE. High versus low dose oral isotretinoin in the treatment of cutaneous and genital warts. Dermatol Ther. 2022 Dec;35(12):e15964. [PubMed: 36346210]107.Olguín-García MG, Peralta-Pedrero ML, Morales-Sánchez MA, Vega-Memije E, Lucio VMB. A Double-Blind Randomized Study of Two Doses of Oral Isotretinoin in the Treatment of Recalcitrant Facial Flat Warts: Impact on Quality of Life, Anxiety, and Depression. Health Sci Rep. 2025 Apr;8(4):e70684. [PMC free article: PMC12010138] [PubMed: 40260029]108.Oren-Shabtai M, Snast I, Noyman Y, Lapidoth M, Sherman S, Mimouni D, Hodak E, Levi A. Topical and systemic retinoids for the treatment of cutaneous viral warts: A systematic review and meta-analysis. Dermatol Ther. 2021 Jan;34(1):e14637. [PubMed: 33278051]109.Murray ML, Meadows J, Doré CJ, Copas AJ, Haddow LJ, Lacey C, Jit M, Soldan K, Bennett K, Tetlow M, Nathan M, Gilson R. Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial). BMC Med Res Methodol. 2018 Nov 06;18(1):125. [PMC free article: PMC6220496] [PubMed: 30400777]110.Tyring S, Edwards L, Cherry LK, Ramsdell WM, Kotner S, Greenberg MD, Vance JC, Barnum G, Dromgoole SH, Killey FP, Toter T. Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. Arch Dermatol. 1998 Jan;134(1):33-8. [PubMed: 9449907]111.Petersen CS, Weismann K. Quercetin and kaempherol: an argument against the use of podophyllin? Genitourin Med. 1995 Apr;71(2):92-3. [PMC free article: PMC1195461] [PubMed: 7744421]112.Tatti S, Swinehart JM, Thielert C, Tawfik H, Mescheder A, Beutner KR. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol. 2008 Jun;111(6):1371-9. [PubMed: 18515521]113.Schöfer H, Tatti S, Lynde CW, Skerlev M, Hercogová J, Rotaru M, Ballesteros J, Calzavara-Pinton P. Sinecatechins and imiquimod as proactive sequential therapy of external genital and perianal warts in adults. Int J STD AIDS. 2017 Dec;28(14):1433-1443. [PubMed: 28566057]114.Godley MJ, Bradbeer CS, Gellan M, Thin RN. Cryotherapy compared with trichloroacetic acid in treating genital warts. Genitourin Med. 1987 Dec;63(6):390-2. [PMC free article: PMC1194123] [PubMed: 3323028]115.Fichman Y, Levi A, Hodak E, Halachmi S, Mazor S, Wolf D, Caplan O, Lapidoth M. Efficacy of pulsed dye laser treatment for common warts is not influenced by the causative HPV type: a prospective study. Lasers Med Sci. 2018 May;33(4):773-777. [PubMed: 29218494]116.Iranmanesh B, Khalili M, Zartab H, Amiri R, Aflatoonian M. Laser therapy in cutaneous and genital warts: A review article. Dermatol Ther. 2021 Jan;34(1):e14671. [PubMed: 33314577]117.He Y, Gao W, Cai F, Zhu Y, Zuo R, Liu H, Gao Y. Successful treatment of refractory oral condyloma acuminatum through laser-photodynamic therapy combination. Photodiagnosis Photodyn Ther. 2024 Apr;46:104005. [PubMed: 38373470]118.Qu Z, Cui G, Wang Z, Liu M, Lin X. Combination of biopsy forceps excision and ALA-PDT for the treatment of cervical condylomata acuminata. Photodiagnosis Photodyn Ther. 2024 Apr;46:104002. [PubMed: 38367921]119.Xie F, Yu HS, Wang R, Wang D, Li YM, Wen HY, Du JB, Ba W, Meng XF, Yang J, Lin BW, Li HJ, Li CX, Zhang LG, Fang XD, Zhao H. Photodynamic Therapy for Genital Warts Causes Activation of Local Immunity. J Cutan Med Surg. 2019 Jul/Aug;23(4):370-379. [PubMed: 31010295]120.Tu P, Zhang H, Zheng H, Gu H, Xu J, Tao J, Wang H, Zhu X, Wang X. 5-Aminolevulinic photodynamic therapy versus carbon dioxide laser therapy for small genital warts: A multicenter, randomized, open-label trial. J Am Acad Dermatol. 2021 Mar;84(3):779-781. [PubMed: 31374308]121.Kechichian E, Helou E, Sarkis J, Hayek C, Labaki C, Nemr E, Tomb R. The place of 5-aminolaevulinic acid-photodynamic therapy in the treatment landscape of urethral warts: A systematic review. Photodiagnosis Photodyn Ther. 2021 Mar;33:102204. [PubMed: 33529745]122.Zhang H, Shi L, Zhang Y, Wang P, Zhang G, Cao Y, Zhou Z, Wang X. Modified photodynamic therapy to minimize pain in the treatment of condylomata acuminata: A prospective, randomized, self-controlled study. Photodiagnosis Photodyn Ther. 2020 Dec;32:101915. [PubMed: 32634656]123.Li Pomi F, D'Aloja A, Di Tano A, Vaccaro M, Borgia F. Pediatric genital warts successfully treated with photodynamic therapy. Dermatol Reports. 2025 May 23;17(2) [PMC free article: PMC12210356] [PubMed: 39969056]124.Mestrovic T, Sviben M, Zember S, Drenjancevic D. Topical medication as an initial therapeutic option for protruding and non-protruding condylomata acuminata of the distal urethra. BMJ Case Rep. 2021 Sep 21;14(9) [PMC free article: PMC8458332] [PubMed: 34548297]125.Scheinfeld N. Update on the treatment of genital warts. Dermatol Online J. 2013 Jun 15;19(6):18559. [PubMed: 24011309]126.Prayogo SA, Andrew H, Cong S, Intaran KDA. Photodynamic therapy in the treatment of condyloma acuminata: A systematic review of clinical trials. Int J STD AIDS. 2023 Feb;34(2):76-86. [PubMed: 36420589]127.Batista CS, Atallah AN, Saconato H, da Silva EM. 5-FU for genital warts in non-immunocompromised individuals. Cochrane Database Syst Rev. 2010 Apr 14;2010(4):CD006562. [PMC free article: PMC7206224] [PubMed: 20393949]128.Malvasi A, Tinelli A, Buia A, De Luca GF. Possible long-term teratogenic effect of isotretinoin in pregnancy. Eur Rev Med Pharmacol Sci. 2009 Sep-Oct;13(5):393-6. [PubMed: 19961047]129.Choi JS, Koren G, Nulman I. Pregnancy and isotretinoin therapy. CMAJ. 2013 Mar 19;185(5):411-3. [PMC free article: PMC3602257] [PubMed: 23296582]130.Belgam Syed SY, Lipoff JB, Chatterjee K. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 8, 2023. Acrochordon. [PubMed: 28846244]131.Konstantinou MP, Krasagakis K. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 14, 2023. Benign Familial Pemphigus (Hailey-Hailey Disease) [PubMed: 36256785]132.Chua RF, Pico J. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 31, 2023. Dermal Melanocytosis. [PubMed: 32491340]133.O'Mahony C, Gomberg M, Skerlev M, Alraddadi A, de Las Heras-Alonso ME, Majewski S, Nicolaidou E, Serdaroğlu S, Kutlubay Z, Tawara M, Stary A, Al Hammadi A, Cusini M. Position statement for the diagnosis and management of anogenital warts. J Eur Acad Dermatol Venereol. 2019 Jun;33(6):1006-1019. [PMC free article: PMC6593709] [PubMed: 30968980]134.Irshad U, Puckett Y. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr 14, 2023. Giant Condylomata Acuminata of Buschke and Lowenstein. [PMC free article: PMC560714] [PubMed: 32809549]135.Tudor ME, Al Aboud AM, Leslie SW, Gossman W. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 17, 2024. Syphilis. [PubMed: 30521201]136.Saleh D, Yarrarapu SNS, Sharma S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 28, 2023. Herpes Simplex Type 1. [PubMed: 29489260]137.Mathew Jr J, Sapra A. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Mar 13, 2024. Herpes Simplex Type 2. [PubMed: 32119314]138.Arnold DL, Krishnamurthy K. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Oct 29, 2024. Lichen Planus. [PubMed: 30252382]139.Ramos Santillan V, Kaur A, Menon G, Babiker HM, Cagir B. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr 12, 2025. Anal Carcinoma. [PubMed: 28722921]140.Fowler JR, Maani EV, Dunton CJ, Gasalberti DP, Jack BW. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Nov 12, 2023. Cervical Cancer. [PubMed: 28613745]141.Jamal Z, Anjum F. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr 27, 2023. Oropharyngeal Squamous Cell Carcinoma. [PubMed: 33085415]142.Kaltenecker B, Dunton CJ, Tikaria R. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Mar 1, 2023. Vaginal Cancer. [PubMed: 32644552]143.Capria A, Tahir N, Fatehi M. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 9, 2023. Vulvar Cancer. [PubMed: 33620867]144.Badri T, Gandhi GR. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Mar 27, 2023. Molluscum Contagiosum. [PubMed: 28722927]145.Macri A, Kwan E, Tanner LS. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 19, 2024. Cutaneous Angiofibroma. [PubMed: 29494077]146.Love LW, Badri T, Ramsey ML. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr 14, 2023. Pearly Penile Papule. [PubMed: 28723057]147.Weir CB, St.Hilaire NJ. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 8, 2023. Epidermal Inclusion Cyst. [PubMed: 30335343]148.Irizarry L, Velasquez J, Wray AA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 22, 2023. Chancroid. [PubMed: 30020703]149.Santiago-Wickey JN, Crosby B. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Mar 12, 2023. Granuloma Inguinale. [PubMed: 30020678]150.Leslie SW, Vinod J. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jun 22, 2025. Lymphogranuloma Venereum Infection. [PMC free article: PMC544283] [PubMed: 31335003]151.Garcia MR, Leslie SW, Wray AA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr 20, 2024. Sexually Transmitted Infections. [PubMed: 32809643]152.Roett MA. Genital Ulcers: Differential Diagnosis and Management. Am Fam Physician. 2020 Mar 15;101(6):355-361. [PubMed: 32163252]153.Pandey A, Sonthalia S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 31, 2023. Skin Tags. [PubMed: 31613504]154.Le C, Thomas A, Lui F. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 4, 2025. Neurofibromatosis. [PubMed: 29083784]155.Czelusta A, Yen-Moore A, Van der Straten M, Carrasco D, Tyring SK. An overview of sexually transmitted diseases. Part III. Sexually transmitted diseases in HIV-infected patients. J Am Acad Dermatol. 2000 Sep;43(3):409-32; quiz 433-6. [PubMed: 10954653]156.Nebesio CL, Mirowski GW, Chuang TY. Human papillomavirus: clinical significance and malignant potential. Int J Dermatol. 2001 Jun;40(6):373-9. [PubMed: 11589741]157.Orlando G, Fasolo MM, Beretta R, Merli S, Cargnel A. Combined surgery and cidofovir is an effective treatment for genital warts in HIV-infected patients. AIDS. 2002 Feb 15;16(3):447-50. [PubMed: 11834957]158.Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):698-702. [PMC free article: PMC6818701] [PubMed: 31415491]159.Kaliterna V, Barisic Z. Genital human papillomavirus infections. Front Biosci (Landmark Ed). 2018 Mar 01;23(9):1587-1611. [PubMed: 29293452]160.Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ, Lindsay BR, Kuter BJ, Perez G, Dominiak-Felden G, Saah AJ, Drury R, Das R, Velicer C. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin Infect Dis. 2016 Aug 15;63(4):519-27. [PMC free article: PMC4967609] [PubMed: 27230391]161.Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JM, Cummings T, Donovan B, Fairley CK, Flagg EW, Johnson AM, Kahn JA, Kavanagh K, Kjaer SK, Kliewer EV, Lemieux-Mellouki P, Markowitz L, Mboup A, Mesher D, Niccolai L, Oliphant J, Pollock KG, Soldan K, Sonnenberg P, Tabrizi SN, Tanton C, Brisson M. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015 May;15(5):565-80. [PMC free article: PMC5144106] [PubMed: 25744474]162.Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018 May 09;5(5):CD009069. [PMC free article: PMC6494566] [PubMed: 29740819]163.Mariani L, Vici P, Suligoi B, Checcucci-Lisi G, Drury R. Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review. Adv Ther. 2015 Jan;32(1):10-30. [PMC free article: PMC4311067] [PubMed: 25620536]164.Pei J, Shu T, Wu C, Li M, Xu M, Jiang M, Zhu C. Impact of human papillomavirus vaccine on cervical cancer epidemic: Evidence from the surveillance, epidemiology, and end results program. Front Public Health. 2022;10:998174. [PMC free article: PMC9859059] [PubMed: 36684904]165.Guo T, Eisele DW, Fakhry C. The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer. Cancer. 2016 Aug 01;122(15):2313-23. [PMC free article: PMC4956510] [PubMed: 27152637]166.Mattis A, Beydoun H, Dobrydneva Y, Ganjoo R. Investigating the Efficacy of HPV Vaccines in Preventing Cervical Cancer from 2006 to 2018 in the US: A SEER Data Set Analysis. Rev Recent Clin Trials. 2023;18(3):214-222. [PMC free article: PMC10514505] [PubMed: 37046192]167.Guo F, Cofie LE, Berenson AB. Cervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine Introduction. Am J Prev Med. 2018 Aug;55(2):197-204. [PMC free article: PMC6054889] [PubMed: 29859731]168.Rafael TS, Rotman J, Brouwer OR, van der Poel HG, Mom CH, Kenter GG, de Gruijl TD, Jordanova ES. Immunotherapeutic Approaches for the Treatment of HPV-Associated (Pre-)Cancer of the Cervix, Vulva and Penis. J Clin Med. 2022 Feb 19;11(4) [PMC free article: PMC8876514] [PubMed: 35207374]169.Kamolratanakul S, Pitisuttithum P. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. Vaccines (Basel). 2021 Nov 30;9(12) [PMC free article: PMC8706722] [PubMed: 34960159]170.Elst L, Albersen M. HPV Vaccination: Does It Have a Role in Preventing Penile Cancer and Other Preneoplastic Lesions? Semin Oncol Nurs. 2022 Jun;38(3):151284. [PubMed: 35577640]171.Cheng L, Wang Y, Du J. Human Papillomavirus Vaccines: An Updated Review. Vaccines (Basel). 2020 Jul 16;8(3) [PMC free article: PMC7565290] [PubMed: 32708759]172.Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, Muñoz N, Schiffman M, Bosch FX. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine. 2008 Aug 19;26 Suppl 10(0 10):K17-28. [PMC free article: PMC4366004] [PubMed: 18847554]173.Berman TA, Schiller JT. Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases. Cancer. 2017 Jun 15;123(12):2219-2229. [PubMed: 28346680]174.Gravitt PE, Winer RL. Natural History of HPV Infection across the Lifespan: Role of Viral Latency. Viruses. 2017 Sep 21;9(10) [PMC free article: PMC5691619] [PubMed: 28934151]175.Hornor G. Ano-genital warts in children: Sexual abuse or not? J Pediatr Health Care. 2004 Jul-Aug;18(4):165-70. [PubMed: 15224040]176.Bussen S, Sütterlin M, Schmidt U, Bussen D. Anogenital Warts in Childhood - Always a Marker for Sexual Abuse? Geburtshilfe Frauenheilkd. 2012 Jan;72(1):43-48. [PMC free article: PMC4168266] [PubMed: 25253903]177.Psomiadou V, Iavazzo C, Douligeris A, Fotiou A, Prodromidou A, Blontzos N, Karavioti E, Vorgias G. An Alternative Treatment for Vaginal Cuff Wart: a Case Report. Acta Medica (Hradec Kralove). 2020;63(1):49-51. [PubMed: 32422116]178.Hosseini MS, Sadeqi A, Heidari Z, Boozari M. A Comprehensive Review of Biologically Active Natural Products on Human Papillomavirus (HPV) at a Glance. Phytother Res. 2025 May;39(5):2262-2290. [PubMed: 40127892]179.Cusini M, Micali G, Lacarrubba F, Puviani M, Barcella A, Milani M. Efficacy and tolerability of nitric-zinc complex in the treatment of external genital warts and "difficult-to-treat" warts: a "proof of concept", prospective, multicentre, open study. G Ital Dermatol Venereol. 2015 Dec;150(6):643-8. [PubMed: 26513041]180.Pontini P, Mastorino L, Gaspari V, Granger C, Ramoni S, Delmonte S, Evangelista V, Cusini M. A Multicentre, Randomised Clinical Trial to Compare a Topical Nitrizinc® Complex Solution Versus Cryotherapy for the Treatment of Anogenital Warts. Dermatol Ther (Heidelb). 2020 Oct;10(5):1063-1073. [PMC free article: PMC7477018] [PubMed: 32734366]181.Hernandez BY, Shvetsov YB, Goodman MT, Wilkens LR, Thompson PJ, Zhu X, Tom J, Ning L. Genital and extra-genital warts increase the risk of asymptomatic genital human papillomavirus infection in men. Sex Transm Infect. 2011 Aug;87(5):391-5. [PMC free article: PMC4398571] [PubMed: 21602516]182.Pamnani SJ, Sudenga SL, Rollison DE, Ingles DJ, Abrahamsen M, Villa LL, Lazcano-Ponce E, Huang Y, Borenstein A, Giuliano AR. Recurrence of Genital Infections With 9 Human Papillomavirus (HPV) Vaccine Types (6, 11, 16, 18, 31, 33, 45, 52, and 58) Among Men in the HPV Infection in Men (HIM) Study. J Infect Dis. 2018 Sep 08;218(8):1219-1227. [PMC free article: PMC6455897] [PubMed: 29800222]183.Hernandez BY, Wilkens LR, Zhu X, Thompson P, McDuffie K, Shvetsov YB, Kamemoto LE, Killeen J, Ning L, Goodman MT. Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis. 2008 Jun;14(6):888-94. [PMC free article: PMC2600292] [PubMed: 18507898]184.Trottier H, Ferreira S, Thomann P, Costa MC, Sobrinho JS, Prado JC, Rohan TE, Villa LL, Franco EL. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res. 2010 Nov 01;70(21):8569-77. [PMC free article: PMC4068337] [PubMed: 20978200]185.Yorulmaz A, Tamer E, Kulcu Cakmak S. Smoking: Is it a Risk Factor for Common Warts? Curr Health Sci J. 2020 Jan-Mar;46(1):5-10. [PMC free article: PMC7323726] [PubMed: 32637159]186.Kaderli R, Schnüriger B, Brügger LE. The impact of smoking on HPV infection and the development of anogenital warts. Int J Colorectal Dis. 2014 Aug;29(8):899-908. [PubMed: 24935346]187.Vaccarella S, Herrero R, Snijders PJ, Dai M, Thomas JO, Hieu NT, Ferreccio C, Matos E, Posso H, de Sanjosé S, Shin HR, Sukvirach S, Lazcano-Ponce E, Muñoz N, Meijer CJ, Franceschi S., IARC HPV Prevalence Surveys (IHPS) Study Group. Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol. 2008 Jun;37(3):536-46. [PubMed: 18316350]188.Hariri S, Warner L. Condom use and human papillomavirus in men. J Infect Dis. 2013 Aug 01;208(3):367-9. [PMC free article: PMC7523497] [PubMed: 23644282]189.Pierce Campbell CM, Lin HY, Fulp W, Papenfuss MR, Salmerón JJ, Quiterio MM, Lazcano-Ponce E, Villa LL, Giuliano AR. Consistent condom use reduces the genital human papillomavirus burden among high-risk men: the HPV infection in men study. J Infect Dis. 2013 Aug 01;208(3):373-84. [PMC free article: PMC3699010] [PubMed: 23644283]190.Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, Koutsky LA. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006 Jun 22;354(25):2645-54. [PubMed: 16790697]191.Nielson CM, Harris RB, Nyitray AG, Dunne EF, Stone KM, Giuliano AR. Consistent condom use is associated with lower prevalence of human papillomavirus infection in men. J Infect Dis. 2010 Aug 15;202(3):445-51. [PubMed: 20569156]192.Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis. 2002 Nov;29(11):725-35. [PubMed: 12438912]193.Muffarrej D, Khattab E, Najjar R. Successful treatment of genital warts with cidofovir cream in a pediatric patient with Fanconi anemia. J Oncol Pharm Pract. 2020 Jul;26(5):1234-1236. [PubMed: 31718429]194.Hengge UR, Tietze G. Successful treatment of recalcitrant condyloma with topical cidofovir. Sex Transm Infect. 2000 Apr;76(2):143. [PMC free article: PMC1758281] [PubMed: 10858720]195.Schürmann D, Bergmann F, Temmesfeld-Wollbrück B, Grobusch MP, Suttorp N. Topical cidofovir is effective in treating extensive penile condylomata acuminata. AIDS. 2000 May 26;14(8):1075-6. [PubMed: 10853999]196.Blaizot R, Dutkiewicz AS, Guillet S, Pham-Ledard A, Beylot-Barry M. Intravenous cidofovir for diffuse genital warts in the setting of multifactorial immunosuppression. J Eur Acad Dermatol Venereol. 2017 Mar;31(3):e162-e163. [PubMed: 27527116]197.Luria L, Cardoza-Favarato G. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 16, 2023. Human Papillomavirus. [PubMed: 28846281]

Disclosure: Stephen Leslie declares no relevant financial relationships with ineligible companies.

Disclosure: Hussain Sajjad declares no relevant financial relationships with ineligible companies.

Disclosure: Sandeep Kumar declares no relevant financial relationships with ineligible companies.

Copyright © 2025, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.

Bookshelf ID: NBK441884PMID: 28722914 Share

Views

• PubReader
• Print View
• Cite this PageLeslie SW, Sajjad H, Kumar S. Condylomata Acuminata (Genital Warts) [Updated 2025 Dec 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.

In this Page

• Continuing Education Activity
• Introduction
• Etiology
• Epidemiology
• Pathophysiology
• Histopathology
• History and Physical
• Evaluation
• Treatment / Management
• Differential Diagnosis
• Prognosis
• Complications
• Deterrence and Patient Education
• Pearls and Other Issues
• Enhancing Healthcare Team Outcomes
• Review Questions
• References

Related information

• PMCPubMed Central citations
• PubMedLinks to PubMed

Similar articles in PubMed

• Vesicoureteral Reflux.[StatPearls. 2025]Vesicoureteral Reflux.Leslie SW, Aeddula NR. StatPearls. 2025 Jan
• Screening for the prevention and early detection of cervical cancer: systematic reviews to inform an update to recommendations by the Canadian Task Force on Preventive Health Care.[Syst Rev. 2025]Screening for the prevention and early detection of cervical cancer: systematic reviews to inform an update to recommendations by the Canadian Task Force on Preventive Health Care.Pillay J, Gates A, Guitard S, Zakher B, Sim S, Vandermeer B, Hartling L. Syst Rev. 2025 Oct 28; 14(1):206. Epub 2025 Oct 28.
• Prescription of Controlled Substances: Benefits and Risks.[StatPearls. 2025]Prescription of Controlled Substances: Benefits and Risks.Preuss CV, Kalava A, King KC. StatPearls. 2025 Jan
• Mid Forehead Brow Lift(Archived).[StatPearls. 2025]Mid Forehead Brow Lift(Archived).Patel BC, Malhotra R. StatPearls. 2025 Jan
• Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis.[Cochrane Database Syst Rev. 2025]Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis.Bergman H, Henschke N, Arevalo-Rodriguez I, Buckley BS, Crosbie EJ, Davies JC, Dwan K, Golder SP, Loke YK, Probyn K, et al. Cochrane Database Syst Rev. 2025 Nov 24; 11(11):CD015364. Epub 2025 Nov 24.

See reviews...See all...

Recent Activity

ClearTurn OffTurn On

• Condylomata Acuminata (Genital Warts) - StatPearlsCondylomata Acuminata (Genital Warts) - StatPearls

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more... Follow NCBI Twitter Facebook LinkedIn GitHub NCBI Insights Blog

Connect with NLM

• Twitter
• Facebook
• Youtube

National Library of Medicine 8600 Rockville Pike Bethesda, MD 20894

Web Policies FOIA HHS Vulnerability Disclosure

Help Accessibility Careers

• NLM
• NIH
• HHS
• USA.gov